Literature DB >> 9466490

Phosphatases and tumorigenesis.

R Parsons1.   

Abstract

Phosphatases are regulatory enzymes that antagonize the action of kinases within the cell. An understanding of the contribution of kinases to cancer has emerged during the past two decades; however, our understanding of phosphatases in cancer has lagged behind. Currently, three phosphatases have been implicated in the etiology of tumors: protein phosphatase 2A, CDC25A/B, and PTEN (or MMAC1). Protein phosphatase 2A and PTEN behave as tumor suppressors, whereas CDC25A and -B act as oncogenes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466490     DOI: 10.1097/00001622-199801000-00014

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  18 in total

Review 1.  Cdc25 as a potential target of anticancer agents.

Authors:  J W Eckstein
Journal:  Invest New Drugs       Date:  2000-05       Impact factor: 3.850

Review 2.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

3.  The cell cycle-regulatory CDC25A phosphatase inhibits apoptosis signal-regulating kinase 1.

Authors:  X Zou; T Tsutsui; D Ray; J F Blomquist; H Ichijo; D S Ucker; H Kiyokawa
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

4.  Neuroprotectin D1 induces dephosphorylation of Bcl-xL in a PP2A-dependent manner during oxidative stress and promotes retinal pigment epithelial cell survival.

Authors:  Rajee Antony; Walter J Lukiw; Nicolas G Bazan
Journal:  J Biol Chem       Date:  2010-04-02       Impact factor: 5.157

5.  Hypomyelination and increased activity of voltage-gated K(+) channels in mice lacking protein tyrosine phosphatase epsilon.

Authors:  A Peretz; H Gil-Henn; A Sobko; V Shinder; B Attali; A Elson
Journal:  EMBO J       Date:  2000-08-01       Impact factor: 11.598

6.  PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus.

Authors:  F Kimura; J Watanabe; H Hata; T Fujisawa; Y Kamata; Y Nishimura; T Jobo; H Kuramoto
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-20       Impact factor: 4.553

Review 7.  Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

Review 8.  A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.

Authors:  Hugh K Arnold; Rosalie C Sears
Journal:  Cancer Metastasis Rev       Date:  2008-06       Impact factor: 9.264

9.  Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression.

Authors:  S W Lee; C L Reimer; L Fang; M L Iruela-Arispe; S A Aaronson
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 5.069

10.  From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle.

Authors:  Claude Gérard; Albert Goldbeter
Journal:  Front Physiol       Date:  2012-11-02       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.